|
|
|
27.02.26 - 11:42
|
Observe Medical ASA: Second half and full year interim report (Cision)
|
|
|
Oslo, February 27, 2026 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the second half and the full year of 2025.
Highlights
· Revenue growth: UnoMeter™ portfolio revenues of NOK 7.5 million in the second half, representing an increase of 69% from the same period in 2024. For the full year the Company recorded revenues from the UnoMeter™ portfolio of NOK 18.8 million, a growth of NOK 7.3 million / +64%.
· Successful recapitalisation: The Group raised NOK 58.5 million in gross proceeds, where NOK 50.5 million was settled in cash through...
|
|
|
|
|
27.02.26 - 08:48
|
Publication of year-end report 2025 (Cision)
|
|
|
OSLO, NORWAY – February 27, 2026: Genetic Analysis AS ("GA" or the "Company") hereby publishes the year-end report for 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.
Ronny Hermansen, CEO of Genetic Analysis, comments:
“The fourth quarter reflects continued execution of our long-term growth strategy, with progress in both commercial expansion and product development. We are advancing collaborations with industry partners, further strengthening the position of GA-map® technology in microbiome-related clinical...
|
|
|
|
|
26.02.26 - 16:12
|
Clarification regarding the publication date of the year-end report 2025 (Cision)
|
|
|
OSLO, NORWAY – February 26, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that the year-end report for 2025 will be published on Friday, 27 February 2026.
The Company's financial calendar for 2025 was included in the interim report for the first quarter of 2025, in which it was stated that the year-end report for 2025 would be published on 27 February 2026. This date has also been published on the Company's website and on Spotlight Stock Market's company page.
However an incorrect publication date (25 February 2026) was stated in the interim report for the third quarter of...
|
|
|
26.02.26 - 07:45
|
Oncoinvent ASA: Second half 2025 results (PR Newswire)
|
|
|
OSLO, Norway, Feb. 26, 2026 /PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.......
|
|
|
26.02.26 - 07:00
|
Arctic Bioscience – Q4 2025 Operational update – Positive outlook for 2026 (Cision)
|
|
|
Highlights Q4 2025:
· Strong ending to the year with quarterly sales revenue of NOK 13,9 million
· Solid order intake into 2026 for the nutraceutical business
· Positive pilot study related to glaucoma received international attention
· Partner search and dialogues for HRO350 is given great attention
· Cost-focus resulted in significantly lower operational costs in 2025
Arctic Bioscience had a strong ending to 2025 with quarterly revenue from the nutraceutical business of NOK 13,9 million. Total revenue for the year was somewhat lower than in 2024, ending at NOK 42,6 million....
|
|
|
25.02.26 - 16:48
|
Nordhealth AS - Invitation to Q4 2025 presentation (Cision)
|
|
|
Nordhealth will report and present its Q4 2025 results on Tuesday the 3rd of March 2026.
The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 3rd of March at 13:00 CET.
Please use the following link to attend: https://us02web.zoom.us/j/86230116204
The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q4/2025 will be available on 3rd March 2026 at 07:30 CET on www.newsweb.no (https://publish.ne.cision.com/l/uxskchlrc/publish.ne.cision.com/l/afkpudtpe/...
|
|
|
|
|
24.02.26 - 12:24
|
Lytix Biopharma AS - New share capital registered (Cision)
|
|
|
Oslo, Norway, 24 February 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 10 February 2026 regarding the results of a subsequent offering of new shares (the "Subsequent Offering"), raising NOK 16,306,227 in gross proceeds.
The share capital increase relating to the Subsequent Offering has been registered today with the Norwegian Register of Business Enterprises. In total, 1,811,803 shares (the "Offer Shares") have been issued through the Subsequent Offering. The Company's new share capital is NOK 7,690,000.50,...
|
|
|
|
|
23.02.26 - 13:12
|
Arctic Bioscience – Invitation to presentation of Q4 2025 operational update (Cision)
|
|
|
Arctic Bioscience will publish its Q4 2025 operational update on Thursday 26[th] of February 2026, at 07:00 CET.
The same day at 10:00 CET, the Company will host a webcast to present the operational update. Following the presentation, it will be opened for questions from the audience.
Webcast details:
Date: Thursday 26[th] of February 2026
Time: 10:00 CET
Format: Webcast and Q&A
Language: Norwegian/English
The presentation can be accessed with the link below:
https://events.teams.microsoft.com/event/14063048-ef68-47fa-a928-7b6060c7ee61@ce618813-5158-40b5-b6d0-...
|
|
|
20.02.26 - 19:33
|
Vistin Pharma ASA: Mandatory notification of trade (GlobeNewswire EN)
|
|
|
Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA....
|
|
|
20.02.26 - 14:33
|
Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial (GlobeNewswire EN)
|
|
|
Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Company's Clinical Trial Application (CTA) for ZIMA-101, a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate....
|
|
|
19.02.26 - 08:01
|
Genetic Analysis AS further strengthens IP portfolio with patent approval in the United States (Cision)
|
|
|
OSLO, NORWAY – February 19, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that its patent application US2017/0369941 has been allowed for grant by the United States Patent and Trademark Office (USPTO). The patent, entitled “METHOD FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP'S”, strengthens the protection of GA's proprietary diagnostic technology. GA maintains an active patent strategy covering all major geographical markets and has previously announced approval in the EU and other countries for this patent.
CEO Ronny Hermansen comments:
”High analytical accuracy...
|
|
|
|
|
18.02.26 - 07:48
|
Photocure ASA: Results for the fourth quarter of 2025 (PR Newswire)
|
|
|
OSLO, Norway, Feb. 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024: NOK 128.6 million), and a commercial EBITDA of NOK 8.4 million (Q4 2024: NOK 3.9 million) for the company. In 2026,......
|
|
|
17.02.26 - 08:54
|
Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC) (Cision)
|
|
|
OSLO, Norway, February 17, 2026 — Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, today announced the publication of a review article in the Journal of ImmunoTherapy of Cancer (JITC).
The article, “Immunobiological mechanisms of action of oncolytic peptides,” was created in collaboration with the company's scientific collaborators at the Institut Gustave Roussy (France) and Fox Chase Cancer Center (USA).
Bridging the Gap in Cancer Treatment
While traditional therapies often struggle with "cold" tumors, or cancers that the immune...
|
|
|
17.02.26 - 07:06
|
Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026 (Cision)
|
|
|
· 9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose
Oslo, Norway, 17 February 2026 – Oncoinvent (OSE: ONCIN), a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it will present final 24‑month results from its RAD-18-001 Phase 1 study of Radspherin[®] after cytoreductive surgery in patients with platinum‑sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of...
|
|
|
16.02.26 - 07:00
|
Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026 (Cision)
|
|
|
Oslo, Norway, 16 February 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is pleased to invite investors, analysts, and stakeholders to a live webcast event at 9:30 AM CET on Thursday, 26 February 2026.
During the webcast, Oncoinvent's management team will present a corporate update and discuss the company's financial results for the second half of 2025.
Second half 2025 webcast:
· Date: Thursday, 26 February 2026
·...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
